RxDoctor Payments Data

David Clark

Interventional Cardiology · Monterey, CANPI 1619952421

Payments from drug & device makers

$2,993in general payments, 2019–2025

Across 99 payments — averaging $30.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$1K
  • Amgen$316
  • Kowa Pharmaceuticals America, Inc.$202
  • Boehringer Ingelheim$178
  • Sanofi-aventis U.S. LLC$138
  • Johnson & Johnson$134
  • plus $778 from 12 others

What the payments were for

  • Travel & lodging$91631%
  • Food & beverage$1,95065%
  • Education$1274%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,993 in reported general payments places this provider in the 25th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$303,760
Medicare patients
382
Services billed
2,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$78,734
Repatha SureclickEvolocumab86$78,481
XareltoRivaroxaban38$48,318
Praluent PenAlirocumab53$32,318
EntrestoSacubitril/Valsartan18$17,161
Ezetimibe312$10,008
Pitavastatin Calcium16$8,653
Atorvastatin Calcium517$5,748
Fludrocortisone Acetate87$4,710
Olmesartan Medoxomil113$2,444
Metoprolol Succinate146$2,008
Nifedipine ErNifedipine42$2,007
Potassium Chloride84$1,779
Nebivolol Hcl32$1,586
Rosuvastatin Calcium151$1,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$78,73466 claims
Johnson & JohnsonXarelto$134$48,31838 claims
NovartisEntresto$116$17,16118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →